Yang Emily C, Koenig Nicole A, Gong Merry, Brotto Lori A, Barr Alasdair M, Lee Terry, Yong Paul J, Geoffrion Roxana
University of British Columbia, Vancouver, BC, Canada.
Centre for Health Evaluation & Outcome Sciences, Vancouver, BC, Canada.
Eur J Obstet Gynecol Reprod Biol X. 2023 Mar 30;18:100192. doi: 10.1016/j.eurox.2023.100192. eCollection 2023 Jun.
Myofascial tenderness is present in most chronic pelvic pain conditions and causes significant distress to patients. Treatment is challenging and often not curative. Cannabis is often used for self-management of chronic pelvic pain. However, we do not know which concentrations and routes of administration are most acceptable to users. We aimed to investigate patterns and willingness of cannabis product use among both habitual users and non-users with myofascial pelvic pain (MPP), to inform therapeutic development.
We conducted a cross-sectional study of questionnaire responses from female patients with MPP from two tertiary pelvic pain centers. We aimed for a convenience sample of 100 responses with representation from both centers. Inclusion criteria were age over 18 with pelvic floor muscle tenderness on standard gynecologic examination. We collected information on demographics, pelvic pain history, cannabis use status, cannabis use preferences, validated opioid misuse risk assessment, and interest in using gynecologic cannabis products and used descriptive analyses.
77/135 (57 %) questionnaire respondents were cannabis users and 58 (43 %) were non-users. Most users consume cannabis daily, (48.1 %) orally (66.2 %) or by smoking (60.7 %), and rated cannabis as effective at relieving pelvic pain. 37/58 (63.8 %) non-cannabis users responded that they would be willing to use cannabis for pelvic pain. Lack of information and potential adverse effects were the most common reasons for unwillingness to use. Approximately 3 of 4 respondents were willing to try vaginal or vulvar application of cannabis products for pelvic pain.
This cross-sectional study describes cannabis use patterns in MPP patients. Topical vulvar and vaginal cannabis products are of strong interest to both cannabis users and non-users and warrant further research.
肌筋膜压痛存在于大多数慢性盆腔疼痛病症中,给患者带来极大痛苦。治疗具有挑战性,且往往无法治愈。大麻常被用于慢性盆腔疼痛的自我管理。然而,我们并不清楚哪种浓度和给药途径最受使用者接受。我们旨在调查患有肌筋膜盆腔疼痛(MPP)的习惯性使用者和非使用者中大麻产品的使用模式和意愿,以为治疗方法的开发提供依据。
我们对来自两个三级盆腔疼痛中心的患有MPP的女性患者的问卷回复进行了横断面研究。我们的目标是获得100份回复的便利样本,且两个中心都有代表。纳入标准为年龄超过18岁,在标准妇科检查中存在盆底肌肉压痛。我们收集了有关人口统计学、盆腔疼痛病史、大麻使用状况、大麻使用偏好、经过验证的阿片类药物滥用风险评估以及对使用妇科大麻产品的兴趣等信息,并进行了描述性分析。
135名问卷受访者中有77名(57%)是大麻使用者,58名(43%)是非使用者。大多数使用者每天使用大麻,48.1%经口服(66.2%)或吸烟(60.7%),并认为大麻对缓解盆腔疼痛有效。58名非大麻使用者中有37名(63.8%)回复称他们愿意使用大麻来治疗盆腔疼痛。缺乏信息和潜在不良反应是最常见的不愿使用的原因。约四分之三的受访者愿意尝试将大麻产品用于阴道或外阴以治疗盆腔疼痛。
这项横断面研究描述了MPP患者的大麻使用模式。外用的外阴和阴道大麻产品引起了大麻使用者和非使用者的浓厚兴趣,值得进一步研究。